Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $52.4 million.

  • Cytokinetics' Other Working Capital Changes rose 110.30% to $268,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 133.82%. This contributed to the annual value of $52.4 million for FY2024, which is 646.37% up from last year.
  • Cytokinetics' Other Working Capital Changes amounted to $52.4 million in FY2024, which was up 646.37% from -$9.6 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Other Working Capital Changes peaked at $87.0 million during FY2020, and registered a low of -$87.0 million during FY2022.
  • Over the past 3 years, Cytokinetics' median Other Working Capital Changes value was -$9.6 million (recorded in 2023), while the average stood at -$14.7 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first soared by 2,344.58% in 2020, then slumped by 300.13% in 2022.
  • Cytokinetics' Other Working Capital Changes (Yearly) stood at $87.0 million in 2020, then slumped by 50.03% to $43.5 million in 2021, then tumbled by 300.13% to -$87.0 million in 2022, then spiked by 88.98% to -$9.6 million in 2023, then spiked by 646.37% to $52.4 million in 2024.